Beijing Business News (Reporter Yao Qian) April 27aztectreasurefreeslotgame, Rongchang Biotech released its first quarter 2024 results announcement, sayingaztectreasurefreeslotgame, due to increased sales of the company's Tatacept and Verdicizumab, the company achieved revenue of approximately 3%aztectreasurefreeslotgame.30 billion yuan, a year-on-year increase of 96aztectreasurefreeslotgame.41%; the loss was approximately 349 million yuan.
On the same day, Rongchang Biotech issued an announcement stating that in view of the fact that the investment amount of the funds promised to be raised after the "Biological New Drug Industrialization Project" has been fully invested, the company plans to use the savings raised by the above-mentioned fundraising project of 11.1471 million yuan (the specific amount is based on the balance of the special account on the day when the funds are transferred out) to permanently replenish working capital for the company's daily production and operations.
